The FDA has granted orphan drug designation to lenabasum for the treatment of dermatomyositis, a systemic autoimmune condition characterized by skin and muscle involvement, according to a press release from Corbus Pharmaceuticals.
An estimated 1 in 100,000 individuals in the United States are affected by dermatomyositis, according to the National Organization for Rare Disorders, with women disproportionately affected more than men and black, Asian and Native American populations exhibiting more severe morbidity.
Often characterized by distinct skin lesions accompanied by erosions,
The FDA has granted orphan drug designation to lenabasum for the treatment of dermatomyositis, a systemic autoimmune condition characterized by skin and muscle involvement, according to a press release from Corbus Pharmaceuticals.
An estimated 1 in 100,000 individuals in the United States are affected by dermatomyositis, according to the National Organization for Rare Disorders, with women disproportionately affected more than men and black, Asian and Native American populations exhibiting more severe morbidity.
Often characterized by distinct skin lesions accompanied by erosions,